Ipsen Pharmaceuticals

liver disease fibrosis NASH NAFLD cancer cirrhosis liver
Biotech

Zydus' phase 3 win tees up filing to challenge Gilead and Ipsen

The win in primary biliary cholangitis clears the path to an FDA filing to establish the company as a challenger to Gilead, Intercept and Ipsen.
Nick Paul Taylor Aug 29, 2025 10:59am
illustration of two arrows going in opposite directions

Ipsen hands back Sutro's ROR1 ADC at center of $875M deal

Aug 8, 2025 6:15am
image of two race cars neck and neck

Ipsen joins ADC race via $900M biobuck deal with Sutro

Apr 2, 2024 7:26am
apoptosis cell death cancer cell death

Cell death biotech folds in 'challenging funding environment'

Jul 11, 2023 4:00am
parachute sunset paragliding chutes

BMS CEO set to leave after 8-year run—Chutes & Ladders

Apr 28, 2023 9:30am
FDA

FDA agrees to give Ipsen's rare disease drug another look

Mar 17, 2023 7:12am